Evidence map›Paper›PMID 38930266›Full record

ReviewMaterials (Basel, Switzerland)2024

Transition-Metal-Oxide-Based Nanozymes for Antitumor Applications.

Huilin Sun, Yang Bai, Donghui Zhao, Jianhao Wang, Lin Qiu

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Targeting glutathione metabolism for tumor radiosensitization (Review).International journal of molecular medicine · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huilin SunSchool of Pharmacy, Changzhou University, Changzhou 213164, China.
Yang BaiSchool of Pharmacy, Changzhou University, Changzhou 213164, China.
Donghui ZhaoSchool of Pharmacy, Changzhou University, Changzhou 213164, China.
Jianhao WangSchool of Pharmacy, Changzhou University, Changzhou 213164, China.
Lin QiuSchool of Pharmacy, Changzhou University, Changzhou 213164, China.ORCID 0000-0002-6514-6006

Funding

Changzhou Leading Innovative Talents Introduction and Cultivation Project CQ20220085National Key Research and Development Program of China 2023YFE0203500National Natural Science Foundation of China 22207011National Natural Science Foundation of China 22375026Postgraduate Research & Practice Innovation Program of Jiangsu Province SJCX23_ 1444
6 · The paper itself

Abstract

Transition metal oxide (TMO)-based nanozymes have appeared as hopeful tools for antitumor applications due to their unique catalytic properties and ability to modulate the tumor microenvironment (TME). The purpose of this review is to provide an overview of the latest progress made in the field of TMO-based nanozymes, focusing on their enzymatic activities and participating metal ions. These nanozymes exhibit catalase (CAT)-, peroxidase (POD)-, superoxide dismutase (SOD)-, oxidase (OXD)-, and glutathione oxidase (GSH-OXD)-like activities, enabling them to regulate reactive oxygen species (ROS) levels and glutathione (GSH) concentrations within the TME. Widely studied transition metals in TMO-based nanozymes include Fe, Mn, Cu, Ce, and the hybrid multimetallic oxides, which are also summarized. The review highlights several innovative nanozyme designs and their multifunctional capabilities. Despite the significant progress in TMO-based nanozymes, challenges such as long-term biosafety, targeting precision, catalytic mechanisms, and theoretical supports remain to be addressed, and these are also discussed. This review contributes to the summary and understanding of the rapid development of TMO-based nanozymes, which holds great promise for advancing nanomedicine and improving cancer treatment.

Indexed as

antitumorchemodynamic therapynanozymetransition metal oxide

Identifiers

PMID38930266
PMCPMC11205014

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.